Literature DB >> 8969523

Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae.

P van der Ley1, J van der Biezen, R Sutmuller, P Hoogerhout, J T Poolman.   

Abstract

The FrpB protein from pathogenic neisseriae is a 77 kDa iron-regulated outer-membrane protein that belongs to the family of TonB-dependent receptors and may have potential as a vaccine component. Comparison between the frpB gene from three different meningococcal strains and a published gonococcal one revealed that the region from residues 350 to 390 displays pronounced sequence variability. In a model for the topology of FrpB in the outer membrane, this region corresponds to loop 7, the longest of the predicted 13 surface-exposed loops. Binding of four out of a total of eight bactericidal monoclonal antibodies to synthetic peptides corresponding to loop 7 showed that their epitopes are located here. The frpB genes from five additional meningococcal strains were cloned and sequenced in this region. Pairwise comparisons showed different degrees of similarity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969523     DOI: 10.1099/13500872-142-11-3269

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  13 in total

1.  Specific ligand binding attributable to individual epitopes of gonococcal transferrin binding protein A.

Authors:  Heather P Masri; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Authors:  Rachel Urwin; Joanne E Russell; Emily A L Thompson; Edward C Holmes; Ian M Feavers; Martin C J Maiden
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

4.  Antigenic heterogeneity and molecular analysis of CopB of Moraxella (Branhamella) catarrhalis.

Authors:  S Sethi; J M Surface; T F Murphy
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Characterization of immunodominant and potentially protective epitopes of Mannheimia haemolytica serotype 1 outer membrane lipoprotein PlpE.

Authors:  Sahlu Ayalew; Anthony W Confer; Emily R Blackwood
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 6.  Iron transport systems in Neisseria meningitidis.

Authors:  Donna Perkins-Balding; Melanie Ratliff-Griffin; Igor Stojiljkovic
Journal:  Microbiol Mol Biol Rev       Date:  2004-03       Impact factor: 11.056

7.  Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989.

Authors:  Gunnstein Norheim; Einar Rosenqvist; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; E Arne Høiby; Tsegaye Alebel; Degu Berhanu; Yarid Merid; Morten Harboe; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  A common gene pool for the Neisseria FetA antigen.

Authors:  Julia S Bennett; Emily A L Thompson; Paula Kriz; Keith A Jolley; Martin C J Maiden
Journal:  Int J Med Microbiol       Date:  2008-08-20       Impact factor: 3.473

9.  An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Authors:  Gunnstein Norheim; Holly Sanders; Jardar W Mellesdal; Idunn Sundfør; Hannah Chan; Carina Brehony; Caroline Vipond; Chris Dold; Rory Care; Muhammad Saleem; Martin C J Maiden; Jeremy P Derrick; Ian Feavers; Andrew J Pollard
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

10.  A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Authors:  L Marsay; C Dold; C A Green; C S Rollier; G Norheim; M Sadarangani; M Shanyinde; C Brehony; A J Thompson; H Sanders; H Chan; K Haworth; J P Derrick; I M Feavers; M C Maiden; A J Pollard
Journal:  J Infect       Date:  2015-05-15       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.